Abivax SA received positive reviews from market analysts today, with multiple reports pointing to significant upside potential. One comprehensive analysis cited 12 buy ratings and no hold or sell ratings, and estimated potential upside of 84%. It set the average price target at $164.00.
Separately, the 12-month average price target was slightly lowered from $161.18 to $159.06. The analysis also noted negative earnings per share (EPS) and cash flow, challenges common for clinical-stage companies investing heavily in research and development.
Abivax is developing obefazimod as its lead candidate. Vilga Financial Planning LLC recently acquired 22,000 shares of the company.